ClinicalTrials.gov
public full text
Public Domain
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)#148739
- A Study of HB0025 Injection in Patients With Advanced Renal Cancer#831543
- Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma#143539
- Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma#852717
- Emerging concepts and recent advances in renal cell neoplasia / Kiril Trpkov, Abbas Agaimy#983096
Record · ID 903840
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive